TEVA

Teva Pharmaceutical Industries Ltd
10.715
-0.045 (-0.42%)
Upgrade to Real-Time
Regular Market
10.715
Volume 871,715
Bid Price
Ask Price
News -
Company Name Stock Ticker Symbol Market Type
Teva Pharmaceutical Industries Ltd TEVA NYSE Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.045 -0.42% 10.715 10:05:29
Open Price Low Price High Price Close Price Prev Close
10.71 10.645 10.745 10.76
Trades Volume VWAP Dollar Volume Avg Volume
3,667 871,715  10.70  9,326,613 -
Last Trade Time Type Quantity Stock Price Currency
10:06:29 10  10.715 USD

Period:

Draw Mode:

Teva Pharmaceutical Industries Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 11.90B 1.11B 1.11B  15.88B  -1.66B 0.38 -9.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - - 0.50%

more financials information »

News Teva Pharmaceutical Indu...

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

TEVA Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Based in Israel, Teva is one of the world's largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company's branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva's portfolio rationalization has resulted in less overall price erosion versus peers.